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Abstract
In 2009, during the influenza A (H1N1) epidemic, there were many reported cases of pulmonary infection with 
severe hypoxemia that was refractory to the ventilatory strategies and rescue therapies commonly used to treat 
patients with severe acute respiratory distress syndrome. Many of those cases were treated with extracorporeal 
membrane oxygenation (ECMO), which renewed international interest in the technique. The Extracorporeal 
Support Study Group was created in order to practice ECMO and to employ it in the treatment of patients with 
severe hypoxemia. In this article, we discuss the indications for using ECMO and report the case of a patient with 
refractory hypoxemia who was successfully treated with ECMO. 
Keywords: Respiratory Insufficiency; Intensive Care Units; Extracorporeal Membrane Oxygenation.
Resumo
Em 2009, muitos casos de infecção pulmonar com hipoxemia grave refratária às estratégias ventilatórias 
habitualmente utilizadas e às manobras de resgate para a síndrome do desconforto respiratório agudo foram 
relatados durante a epidemia por influenza A (H1N1). Em muitos desses pacientes, o uso de extracorporeal 
membrane oxygenation (ECMO, oxigenação extracorpórea por membrana) foi necessário, fato que fez reacender 
o interesse na ECMO globalmente. O Grupo De Estudos em Suporte Extracorpóreo foi criado visando a aprender 
a técnica e a utilizar ECMO no tratamento de pacientes com hipoxemia grave. Neste artigo, são discutidas as 
indicações de ECMO e é relatado o caso de uma paciente com hipoxemia refratária que foi tratada através de ECMO 
de forma bem sucedida. 
Descritores: Insuficiência Respiratória; Unidades de Terapia Intensiva; Circulação Extracorpórea com Oxigenador 
de Membrana.
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Introduction
From an epidemiological standpoint, the 
year 2009 was marked by the novel influenza 
A (H1N1) virus epidemic,(1) and the respiratory 
syndrome caused by the virus reached pandemic 
levels in mid-2009.(2) Mortality from influenza 
A (H1N1) infection was reported to be as high 
as 23% at that time.(3) The leading cause of 
death in patients with acute respiratory distress 
syndrome (ARDS) due to infection with the 
influenza A (H1N1) virus is respiratory failure 
that is refractory to conventional mechanical 
ventilation.(4) The Australian and New Zealand 
Intensive Care Society reported that, between 
June and August of 2009, 201 patients with 
ARDS due to influenza A (H1N1) virus infection 
required mechanical ventilation; of those 201, 
68 (34%) required extracorporeal membrane 
oxygenation (ECMO) for refractory hypoxemia.(5) 
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(12) Enthusiasm for ECMO then began to wane. 
This was due to the apparent lack of benefits 
and, first and foremost, to the high incidence 
of complications, such as bleeding, extremity 
ischemia, hemolysis, and inflammatory response 
activation. However, in recent years, the 
development of new membranes and heparin-
coated systems that are more biocompatible has 
greatly reduced the need for anticoagulation, 
reducing the incidence of bleeding disorders 
and ECMO-induced inflammatory response. 
Likewise, the development of next-generation 
centrifugal pumps reduced the incidence of 
ECMO-associated hemolysis.(13) 
A change in the paradigm for ECMO use 
was recently brought about by the use of ECMO 
during the influenza A (H1N1) epidemic and, 
first and foremost, by the publication of an 
important study conducted in Great Britain(14) 
and involving patients with ARDS. That study 
compared the use of a protective ventilatory 
strategy involving low tidal volume and low 
airway pressure with that of venovenous ECMO 
and lung rest (positive end-expiratory pressure 
of 10-15 cmH2O; peak airway pressure of 
20-25 cmH2O; RR of 10 breaths/min; and FiO2 
of 0.3). In the group of patients treated with 
ECMO, 63% survived with good functional 
capacity for six months, compared with 47% 
in the group of patients treated with the 
conventional protective ventilatory strategy.(14) 
In that study, the patients who were randomly 
selected for ECMO treatment were transferred 
to the Glenfield Hospital, in Leicester, England, 
which is the only center that provided ECMO.
Many patients with refractory hypoxemia 
due to influenza A (H1N1) infection have been 
treated with ECMO, which has renewed interest 
in this life support technique. At facilities 
specializing in neonatal, pediatric, or adult 
care, ECMO is used in patients with respiratory 
failure, as well as in those with heart failure. 
The ECMO technique facilitates gas exchange, 
allowing the lungs to “rest” until the patient 
has recovered from the pathological process and 
minimizing the potentially deleterious effects 
of ventilator-induced lung injury. Therefore, 
ECMO can be considered the definitive rescue 
therapy for patients with refractory hypoxemia, 
given that pulmonary gas exchange can be 
unnecessary during ECMO use. The technique 
consists of removing blood by means of a 
pump (either a centrifugal pump or a peristaltic 
pump) and circulating it through an artificial 
lung (Figure 1). To that end, the technique 
that is most commonly used is the venovenous 
technique, by which venous blood is removed, 
oxygenated, and returned to the venous system 
of the patient, thus providing oxygenation.(6) 
Venoarterial access can also be used. In that case, 
blood is removed from the venous circulation 
and returned to the aorta, thus improving 
cardiac output and gas exchange. 
Cardiorespiratory support with ECMO has 
been described since 1869,(7,8) although the first 
case of an ARDS patient whose survival was 
attributed to ECMO was reported in 1971.(9) The 
first clinical study that compared conventional 
mechanical ventilation with venoarterial 
ECMO involved 90 patients with ARDS and 
was published in 1979, and the mortality 
rate was reported to be above 90% in both 
groups. In the ECMO group, common adverse 
events included bleeding, thromboembolic 
events, and hemolysis.(10) A study conducted 
in 1986 described a venovenous CO2 removal 
technique that allowed the use of mechanical 
ventilation with lower airway pressures and 
minus the adverse events associated with arterial 
cannulation. In that study, the mortality rate for 
patients with ARDS was reported to be 49%.
(11) In a randomized study published in 1994 
and involving 40 patients with ARDS, the CO2 
removal technique was compared with pressure-
controlled ventilation; the technique was found 
to have no beneficial effects on mortality or on 
the incidence of bleeding in the ECMO group.
Figure 1 - Extracorporeal membrane oxygenation 
system. Note the membrane for gas exchange, the 
centrifugal pump, and the console, which regulates 
the blood flow.
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Clinical case
A 14-year-old female patient with a history 
of systemic lupus erythematosus had been 
admitted to the ICU of the HC-FMUSP Institute 
for Children one month prior with a profile of 
respiratory distress and fever. She had previously 
received pulse therapy with methylprednisolone 
and cyclophosphamide for disease control. 
During her ICU stay, her pulmonary function 
worsened, and multidrug-resistant Acinetobacter 
baumannii was isolated from her tracheal 
secretion. After three days, her clinical status 
worsened significantly. She presented with acute 
kidney injury, severe hypoxemia, and septic 
shock, for which she was treated with high doses 
of noradrenaline (0.8 µg • kg−1 • min−1). Despite 
the use of alveolar recruitment maneuvers and 
paralysis with neuromuscular blocking agents, 
ventilation did not improve. The Extracorporeal 
Respiratory Support Group of the HC-FMUSP 
Clinical Emergency and Respiratory ICUs was 
brought in to determine whether the use of 
ECMO was feasible. The ventilation and gas 
exchange parameters before ECMO initiation are 
described in Table 1. Despite a high inspiratory 
pressure and positive end-expiratory pressure, 
the patient presented with severe hypoxemia 
before ECMO initiation, as evidenced by a PaO2/
FiO2 ratio of 40. 
The use of venovenous ECMO was 
recommended, the right femoral and left jugular 
veins were cannulated with 20-F catheters, 
and ECMO was started. After having been 
stabilized, the patient (with the ECMO system 
still in operation) was transported by ambulance 
to the general ICU of the HC-FMUSP. Her 
(14) Finally, also in 2009, a study conducted in 
Australia and New Zealand evaluated 68 patients 
with severe respiratory failure due to influenza A 
(H1N1) infection and treated with ECMO. Of the 
68 patients, 63 were treated with venovenous 
ECMO.  The mean PaO2 of patients at the 
initiation of ECMO was 55 mmHg, with an FiO2 
of 100%, and in-hospital survival was 79%.(5) 
In 2010, with the objective of practicing 
the ECMO technique and using it routinely 
in patients with refractory hypoxemia, the 
Extracorporeal Support Study Group was 
created. The study group comprises health care 
professionals in the Clinical Emergency and 
Respiratory ICUs of the Hospital das Clínicas 
da Faculdade de Medicina da Universidade de 
São Paulo (HC-FMUSP, University of São Paulo 
School of Medicine Hospital das Clínicas), 
located in the city of São Paulo, Brazil, as well 
as health care professionals in the ICU of the 
Sírio-Libanês Hospital ICU, also in São Paulo. 
The physicians, nurses, and physical therapists 
working in those ICUs initially practiced the 
ECMO techniques by conducting experimental 
studies in pigs, with the objective of learning 
how to assemble the system, perform vascular 
cannulation, provide support to patients with 
severe ARDS, and manage ECMO-related 
complications.  In Chart 1, we describe the 
principal criteria used by our study group in 
order to recommend the clinical use of ECMO. 
In 2011, following the training period, we 
began to use ECMO in clinical settings. Below, 
we describe the case of a patient who presented 
with severe refractory hypoxemia and was 
treated with ECMO. 
Chart 1 - Criteria for the use of extracorporeal membrane oxygenation.
Mandatory criteria
Tracheal intubation and mechanical ventilation
Acute onset lung disease
Bilateral pulmonary infiltrate
PaO2/FiO2 ratio < 200 with positive end-expiratory pressure ≥ 10 cmH2O
Reversible lung injury
Complementary criteria (at least one must be met)
PaO2/FIO2 ratio ≤ 50 with an FiO2 = 1, for at least 1 h, with or without the use of rescue therapies (alveolar 
recruitment, inhaled NO, and prone position)
Hypercapnia with pH remaining ≤ 7.20 using an RR ≥ 35 breaths/min (whenever possible), a tidal volume = 
4-6 mL/kg, and a plateau pressure ≤ 30 cmH2O
Murray lung injury score > 3, with worsening of the clinical status
PaO2/FiO2 ratio ≤ 50 with an FiO2 ≥ 0.8 for at least 3 h, despite the use of rescue therapies
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with an FiO2 of 60%.  For the first five days, 
the patient developed severe hypoxemia 
whenever the extracorporeal support was 
reduced. On the sixth day, after a satisfactory 
autonomy test result, ECMO was discontinued, 
and the ventilatory support was progressively 
reduced. On the eighth day, the patient was 
Simplified Acute Physiology Score 3 before 
ICU admission was 79, and her Sequential 
Organ Failure Assessment score was 15, 
demonstrating the severity of her clinical status 
and the high risk of death. Figure 2 shows a 
chest X-ray taken immediately after ECMO 
initiation. A large quantity of blood in the 
tracheal aspirate, together with the decreased 
hemoglobin concentrations and bleeding 
disorder (Table 1), was suggestive of a diagnosis 
of alveolar hemorrhage.  Support with ECMO 
was maintained for six days, during which the 
patient received polymyxin and intravenous 
immunoglobulin for the treatment of pneumonia 
and the underlying disease, respectively. During 
that period, the patient required dialysis with 
continuous hemofiltration, and she was weaned 
from the noradrenaline. Because of her bleeding 
disorder, we chose to maintain the patient on 
ECMO without anticoagulation. No ECMO-
related complications occurred. The patient 
presented with hypertensive pneumothorax in 
the left lung and therefore underwent pigtail 
catheter drainage (Figure 3). 
During ECMO use, we performed daily 
autonomy tests, which consisted of attempts 
at maintaining gas exchange without ECMO 
for 1 h at the same pressures and frequencies, 
Table 1 - Hemodynamic, respiratory, and biochemical data during extracorporeal membrane oxygenation.
Variable Pre-ECMO Day 1 Day 2 Day 3 Day 4 Day 5 Day 6
HR, bpm - 141 124 129 116 130 134
MAP, mmHg - 105 105 109 107 100 94
SpO2, % 85 97 95 95 98 99 100
Mean ECMO blood flow, L/min - 5.4 5.1 5.1 5.2 5.6 4.7
Mean ECMO oxygen flow, L/min - 4.0 3.0 2.0 1.0 0.7 0.6
Mode of ventilation PC PS PS PS PS PS PS
RR, breaths/min 22 32 34 41 22 27 21
Tidal volume, mL 310 200 220 350 400 350 600
Plateau pressure, cmH2O 46 22 20 20 20 20 20
FiO2 100 30 30 30 30 30 30
PEEP, cmH2O 23 15 15 15 15 15 15
pH 7.51 7.39 7.39 7.42 7.48 7.34 7.29
pO2, mmHg 40.8 68.0 50.0 45.7 50.0 83.0 85.0
pCO2, mmHg 35 45 44 42 50 51 42
Base excess, mEq/L 5.6 1.5 1.6 2.1 11.9 10.6 6.0
SaO2, % 81 93 85 82 88 95 95
Lactate, mg/dL 17 10 10 11 19 13 14
Hemoglobin, g/dL - 7.6 5.6 6.4 6.8 7.2 7.9
Platelets, cells/mm3 - 43,000 68,000 70,000 55,000 48,000 112,000
ECMO: extracorporeal membrane oxygenation; MAP: mean arterial pressure; PC: pressure-controlled; PS: pressure support; 
PEEP: positive end-expiratory pressure; pO2: oxygen tension; pCO2: carbon dioxide tension.
Figure 2 - Chest X-ray taken during extracorporeal 
membrane oxygenation use and showing the cannulas 
inserted into the inferior vena cava, through which 
blood is removed, and into the jugular vein, through 
which blood is returned to the patient. ECMO: 
extracorporeal membrane oxygenation.
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extubated. Figure 3 shows a chest X-ray taken 
after extubation. On postadmission day 14, the 
patient was discharged to the infirmary. She was 
using an oxygen catheter at 2 L/min, and her 
SpO2 was 98%. 
In the clinical case reported here, we described 
the successful use of the ECMO technique, 
which should be progressively incorporated into 
the therapeutic armamentarium for patients 
with refractory hypoxemia but requires the 
use of special equipment by a properly trained 
team. The severity of the clinical condition of 
the patient, who presented with multiple organ 
failure and severe ARDS, is commonly associated 
with a high risk of death, pulmonary function 
being a determinant of patient evolution. The 
continuous use of ECMO, even while the patient 
is being transported from one hospital ICU to 
another, allows extracorporeal gas exchange in 
the period during which lung involvement is 
greatest, thus allowing the clinical condition 
and the prognosis to improve. 
The Extracorporeal Support Study Group 
constitutes a pioneering project in Brazil and 
aims not only to treat patients with extremely 
severe respiratory failure but also to develop 
research and instruction activities related to the 
theme. Therefore, the objective of the group is 
to provide multidisciplinary teams with training 
in the aforementioned techniques in order to 
allow health care professionals at other facilities 
to use the method correctly. 
Figure 3 - Chest X-ray taken after clinical improvement 
and extubation.
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